Tafinlar® + Mekinist®
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection
Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation
References
- Tafinlar (dabrafenib) Summary of Product Characteristics.
- Mekinist (trametinib) Summary of Product Characteristics.
Related Content
__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________...Show more
Ask Speakers
Medical Information Request
Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.